Core Viewpoint - The report outlines the progress and evaluation of the "Quality Improvement and Efficiency Enhancement Action Plan" for 2025, emphasizing the company's commitment to high-quality development and investor value enhancement. Group 1: Business Performance - The company achieved operating revenue of 786.69 million yuan in the first half of the year, representing a year-on-year growth of 14.72% [1] - The net profit attributable to shareholders was 213.31 million yuan, with a year-on-year increase of 2.53% [2] - The revenue from surgical treatment products, particularly high-end artificial lenses, grew by 8.23%, while revenue from contact lenses increased by 28.89% due to expanded sales channels [1][2] Group 2: Market Expansion and Product Structure - The company has established an overseas sales network covering Europe, Asia, and South America, enhancing its market competitiveness [2] - The company is actively participating in international industry conferences and promotional activities to strengthen recognition among overseas doctors and patients [2] - The company has launched a new silicone hydrogel contact lens, breaking the monopoly of foreign companies in the Chinese market [3] Group 3: Quality Management and Production Capacity - The company has implemented a comprehensive quality control system to prevent potential issues in products and processes [2] - A special team has been formed to optimize the automated production line for contact lenses, aiming to increase production capacity significantly [3] - The company plans to achieve an annual production capacity of 252 million contact lenses and 500 million sets of molds after the completion of new projects [3] Group 4: Innovation and R&D - R&D investment increased by 21.55% year-on-year, accounting for 10.60% of operating revenue, supporting the development of new products and technologies [3][4] - The company applied for 44 patents during the reporting period, with 26 patents granted, enhancing its technological competitiveness [4] - The company is focusing on developing core technologies and protecting intellectual property to maintain its industry leadership [4] Group 5: Governance and Information Disclosure - The company has revised its governance documents to align with new regulations, enhancing its governance structure [6] - The board of directors has been re-elected to ensure continuity and diversity in decision-making [6] - The company emphasizes high-quality information disclosure to improve transparency and investor trust [7] Group 6: Shareholder Returns - The company has distributed cash dividends totaling 241 million yuan since its listing, reflecting its commitment to shareholder returns [8] - A share buyback program has been initiated, with 142,800 shares repurchased at an average price of 140.36 yuan per share [8] - The company aims to explore mechanisms that balance immediate and long-term shareholder interests [8]

（网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 8 月 28 日（星期四）至 9 月 3 日（星期三）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司投资者邮箱 （investors@ebmedical.com）进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 爱博诺德（北京）医疗科技股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 爱博诺德（北京）医疗科技股份有限公司（以下简称"爱博医疗"或"公司"） 已于 2025 年 8 月 28 日在上海证券交易所网站（www.sse.com.cn）发布了公司《2025 年半年度报告》。为便于广大投资者更全面深入地了解公司 2025 年半年度经营成 果、财务状况，公司计划于 9 月 4 日（星期四）11:00-12:00 举行 2025 年半年度业 绩说明会（以下简称"说明会"），就投资者普 ...

证券代码：688050 证券简称：爱博医疗 公告编号：2025-047 爱博诺德（北京）医疗科技股份有限公司 2025 年半年度募集资金存放与实际使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 （一）募集资金金额及到位时间 根据中国证券监督管理委员会出具的《关于同意爱博诺德（北京）医疗科技 股份有限公司向特定对象发行股票注册的批复》（证监许可〔2025〕774 号）， 爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"或"本公司"） 2024 年度以简易程序向特定对象发行人民币普通股 3,593,615 股，每股发行价格 79.20 元 ， 募 集 资 金 总 额 284,614,308.00 元 ， 扣 除 相 关 发 行 费 用 人 民 币 4,001,997.70 元后，实际募集资金净额为人民币 280,612,310.30 元。2025 年 4 月 29 日，信永中和会计师事务所（特殊普通合伙）对本次发行募集资金到位情况进 行了审验，并出具了《爱博诺德（北京）医疗科技股份 ...

爱博诺德（北京）医疗科技股份有限公司 关于 2025 年度"提质增效重回报"行动方案的 为深入贯彻落实国务院《关于进一步提高上市公司质量的意见》等相关要求， 爱博诺德（北京）医疗科技股份有限公司（以下简称"爱博医疗"或"公司"）积 极践行"以投资者为本"的上市公司发展理念，推动公司高质量发展和投资价值提 升，已于 2025 年 4 月 23 日披露了《2025 年度"提质增效重回报"行动方案》（以 下简称"《行动方案》"）。 2025 年上半年，公司积极落实《行动方案》中的各项工作，聚焦主营业务发展、 推动创新研发成果转化、强化投资者关系管理，有效传递公司长期投资价值。现将 《行动方案》半年度实施进展及评估情况报告如下： 一、聚焦主业，推动高质量发展 2025 年上半年，公司经营成果取得如下进展： （一）夯实主营业务，经营业绩持续增长 面对复杂多变的国内外形势，公司稳健经营，上半年实现营业收入 78,669.11 万 元，同比增长 14.72%。手术治疗产品中，人工晶状体营业收入同比增长 8.23%，"全 视"多焦人工晶状体、"龙晶"有晶体眼人工晶状体等高端产品增长迅速，占比不断 提升；近视防控产品中，"普诺 ...

北京商报讯（记者 王寅浩 实习记者 宋雨盈）8月27日，爱博医疗发布公告称，2025年上半年实现营业 收入7.87亿元，同比增长14.72%；归属于上市公司股东的净利润为2.13亿元，同比增长2.53%；归属于 上市公司股东的扣除非经常性损益的净利润为2.04亿元，同比增长2.63%。 ...

1 / 197 爱博诺德（北京）医疗科技股份有限公司2025 年半年度报告 公司代码：688050 公司简称：爱博医疗 爱博诺德（北京）医疗科技股份有限公司 2025 年半年度报告 爱博诺德（北京）医疗科技股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会董事高级管理人员保证半年度报告内容的真实性、准确性、完整性，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 本公司已在本报告中详细阐述在生产经营过程中可能面临的各种风险因素，敬请参阅"第三 节管理层讨论与分析"之"四、风险因素"相关内容。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人解江冰、主管会计工作负责人郭彦昌及会计机构负责人（会计主管人员）郭彦 昌声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性陈述，不构成本公司对投资者的承诺，敬请 投资者注意 ...

Summary of Key Points Core Viewpoint - Aibo Medical experienced significant trading activity on August 25, with a total of 266,000 shares traded through block transactions, amounting to 19.434 million yuan, at a price of 73.06 yuan per share, reflecting a discount of 7.40% compared to the closing price of the day [2]. Trading Activity - On August 25, Aibo Medical had 6 block trades with a total trading volume of 266,000 shares and a total transaction value of 19.434 million yuan [2]. - The average transaction price was 73.06 yuan, which is 7.40% lower than the closing price of the day [2]. - Institutional trading desks participated in 2 of the transactions, with a total transaction value of 4.2375 million yuan, indicating a net purchase of the same amount [2]. Recent Trading Trends - Over the past three months, Aibo Medical has recorded a total of 27 block trades, with a cumulative transaction value of 150 million yuan [2]. - The closing price of Aibo Medical on the reporting day was 78.90 yuan, showing an increase of 1.52% [2]. - The stock had a turnover rate of 2.59% and a total trading volume of 386 million yuan for the day, with a net outflow of 5.1478 million yuan in main funds [2]. - In the last five days, the stock has increased by 1.53%, with a total net inflow of 9.8642 million yuan [2]. Margin Trading Data - The latest margin financing balance for Aibo Medical is 547 million yuan, which has decreased by 21.2109 million yuan over the past five days, representing a decline of 3.73% [2].

Core Viewpoint - Aibo Medical's stock price increased by 1.52% to 78.90 yuan as of August 25, 2025, with significant trading activity noted [1] Group 1: Stock Performance - Aibo Medical's stock opened at 77.72 yuan, reached a high of 79.11 yuan, and a low of 77.72 yuan, with a trading range of 1.79% on the same day [1] - The total trading volume for the day was 3.86 billion yuan [1] Group 2: Business Overview - Aibo Medical specializes in the research, production, and sales of ophthalmic medical devices, including artificial lenses and orthokeratology lenses [1] - The company operates in sectors such as medical devices and specialized innovation [1] Group 3: Trading Activity - On August 25, Aibo Medical experienced six block trades totaling 266,000 shares, amounting to 19.434 million yuan, with an average transaction price of 73.06 yuan, reflecting a discount of 7.40% compared to the closing price [1] - Institutional accounts purchased 58,000 shares, with a transaction value of 4.2375 million yuan [1] Group 4: Capital Flow - On the same day, Aibo Medical saw a net outflow of 1.6362 million yuan in main funds, while the net inflow over the past five days was 2.6767 million yuan [2]

Company Overview - Aibo Medical's closing price on August 25 was 78.9 yuan, with an increase of 1.52%, resulting in a rolling PE ratio of 40.36 times and a total market value of 15.26 billion yuan [1] - The company ranks 77th in the medical device industry, which has an average PE ratio of 56.14 times and a median of 40.36 times [1] Institutional Holdings - As of the first quarter of 2025, 18 institutions hold shares in Aibo Medical, all of which are funds, with a total holding of 11.0688 million shares valued at 762 million yuan [1] Business Operations - Aibo Medical focuses on the independent research, production, sales, and related services of ophthalmic medical devices, with main products including artificial lenses, surgical products, orthokeratology lenses, myopia control products, contact lenses, and other vision care products [1] Financial Performance - In the latest quarterly report for Q1 2025, Aibo Medical achieved an operating revenue of 357 million yuan, representing a year-on-year increase of 15.07%, while net profit was 92.5581 million yuan, showing a year-on-year decrease of 10.05%, with a gross profit margin of 64.60% [1]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 8月25日，爱博医疗收涨1.52%，收盘价为78.90元，发生6笔大宗交易，合计成交量26.6万股，成交金额 1943.4万元。 第4笔成交价格为73.06元，成交3.00万股，成交金额219.18万元，溢价率为-7.40%，买方营业部为机构 专用，卖方营业部为国联民生证券股份有限公司北京金宝街证券营业部。 第5笔成交价格为73.06元，成交2.80万股，成交金额204.57万元，溢价率为-7.40%，买方营业部为机构 专用，卖方营业部为国联民生证券股份有限公司北京金宝街证券营业部。 第6笔成交价格为73.06元，成交10.00万股，成交金额730.60万元，溢价率为-7.40%，买方营业部为华泰 证券股份有限公司深圳益田路荣超商务中心证券营业部，卖方营业部为国联民生证券股份有限公司北京 金宝街证券营业部。 进一步统计，近3个月内该股累计发生27笔大宗交易，合计成交金额为1.5亿元。该股近5个交易日累计 上涨1.53%，主力资金合计净流出260.54万元。 责任编辑：小浪快报 第1笔成交价格为73.06元，成交5.00万股，成交金额36 ...